▼XELJANZ EULAR 2017: Video highlights

Each year leading researchers and opinion leaders from the rheumatology world gather at one of the key annual events - EULAR - the Annual European Congress of Rheumatology - and 2017 is no exception. Hear a selection of experts give their XELJANZ-related highlights of the congress, and share their thoughts on how this may impact future clinical practice.

Professor Roy Fleischmann

Professor Roy Fleischmann

Professor Fleischmann provides an explanation of the methodology of the ORAL Strategy trial and presents a summary of the results.

Watch now

 

Dr. Peter Nash

Dr Peter Nash

Dr Nash provides insights into the XELJANZ Mode of Action and long term safety profile.

Watch now

 

Dr. Janet Pope

Dr Janet Pope

Dr. Pope discusses the key take home messages on the latest JAK inhibitor data from the Pfizer RA symposium at EULAR, and the implications this data has for clinical management of RA patients.

Watch now

 

Dr. Eduardo Mysler

Dr Eduardo Mysler

Dr. Mysler on the rapid and sustained efficacy of XELJANZ monotherapy.

Watch now

 

Professor Rieke Alten

Professor Rieke Alten

Professor Alten discusses unmet needs in patients with rheumatoid arthitis.

Watch now

 

 

Date of preparation: June 2017   Job code: PP-XEL-GBR-0403